Actively Recruiting
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Led by Peking University First Hospital · Updated on 2025-06-06
50
Participants Needed
2
Research Sites
189 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Multiple Myeloma (MM), the second most common hematological malignancy, continues to pose challenges in precise clinical identification. As a potential solution, nuclear medicine immuno-PET imaging has emerged as a promising approach. However, traditional full-length antibody probes suffer from delayed tumor uptake peaks and low target-to-background ratios, limiting their clinical utility. In our study, a peptide or nanobody targeting BCMA was developed by computer-aided designing, which was subsequently radiolabeled with 68Ga to create a novel molecular probe, 68Ga-MM-BC1. This research aims to overcome the diagnostic limitations of MM and may also offer valuable insights for molecular-targeted imaging in other malignant tumors.
CONDITIONS
Official Title
A Molecular Probe Targeting BCMA for the Clinical Diagnosis of Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Suspected multiple myeloma patients scheduled for bone marrow aspiration or tissue biopsy within the past 3 months
- Able to fully understand and voluntarily participate in the study with signed informed consent
- Able to cooperate with the examination
- Diagnosed symptomatic multiple myeloma patients
- Able to fully understand and voluntarily participate in the study with signed informed consent
- Able to cooperate with the examination
You will not qualify if you...
- Pregnant women
- Individuals unable to understand the examination process
- Individuals unable to cooperate with the examination
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Department of Nuclear Medicine, Peking University First Hospital
Beijing, Beijing Municipality, China, 010000
Actively Recruiting
2
Peking University First Hospital
Beijing, Beijing Municipality, China, 100000
Enrolling by Invitation
Research Team
T
Tianyao Wang, PhD
CONTACT
T
Tingting Yuan, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
CROSSOVER
Primary Purpose
DIAGNOSTIC
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here